The synthesis of new 2,4‐diaminofuro[2,3‐d]pyrimidines with 5‐biphenyl,phenoxyphenyl and tricyclic substitutions as dihydrofolate reductase inhibitors

Nonclassical 2,4‐diamino‐5‐substituted furo[2,3‐d]pyrimidines 4a‐i, 5a‐b and 7a‐f were synthesized as extended aromatic ring appended analogs of previously reported antifolates 1a‐b. The extended aromatic system was designed to better interact with a phenylalanine residue (Phe69) of dihydrofolate reductase from the opportunistic pathogen Pneumocystis carinii to afford potent and selective inhibitors of Pneumocystis carinii dihydrofolate reductase. The target compounds were synthesized by nucleophilic displacement of 2,4‐diamino‐5‐(chloromethyl)furo[2,3‐d]pyrimidine 3 with the appropriate aromatic amine or thiol. The compounds were evaluated as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii, and their selectivity was determined using rat liver dihydrofolate reductase as the mammalian reference. In the C8‐N9 bridged series, compound 4e , with a 3‐(2‐methoxydibenzofuran)‐ side chain, exhibited greatest potency and was more than 3 times as selective for Pneumocystis carinii dihydrofolate reductase compared to rat liver dihydrofolate reductase. Compounds 4b and 4c also exhibited selectivity. Compounds in the C8‐S9 bridged series showed comparable potencies, and each showed higher selectivity for Pneumocystis carinii dihydrofolate reductase compared to rat liver dihydrofolate reductase.     

Synthesis and biological evaluation of 5-arylfuro[2,3-d]pyrimidines as novel dihydrofolate reductase inhibitors

A series of about fifty novel 5-arylfuro[2,3-d]pyrimidine derivatives were synthesized as potential inhibitors of dihydrofolate reductase (DHFR) arising from different species. Weak enzyme inhibition was observed for most of the compounds, with only a few reaching IC50 values less than 30 microM. With regards to antibacterial and anti-malarial potency, only seven compounds showed a modest in vitro activity against some bacteria strains and only three products proved significantly active against P. falciparum.     

Synthesis of three carbon atom bridged 2,4‐diaminopyrrolo[2,3‐d]‐pyrimidines as nonclassical dihydrofolate reductase inhibitors

A series of seven nonclassical three carbon atom bridged 2,4‐diamino‐5‐substituted‐pyrrolo[2,3‐d]‐pyrirnidines 1a‐g were synthesized as potential inhibitors of dihydrofolate reductase. Selective oxidation of diols 7a‐g affords α‐hydroxy ketones 8a‐g. Subsequent condensation with malononitrile gave the requisite 2‐amino‐3‐cyano‐4‐substituted furan precursors 9a‐g. Cyclocondensation with guanidine in refluxing ethanol in one step affords the three carbon atom bridged 2,4‐diamino‐5‐substituted‐pyrrolo[2,3‐d]‐pyrimidines 1a‐g. Preliminary biological results indicated that these compounds showed moderate inhibitory activities against dihydrofolate reductases from Pneumocystis carinii, Toxoplasma gondii, Mycobacterium avium and rat liver with IC₅₀ values in the 0.66 μM ‐ 70.1 μM range and some compounds had marginal selectivity for T. gondii dihydrofolate reductase.     

Synthesis of 2,4‐diaminopyrido[2,3‐d]pyrimidines and 2,4‐diamino‐quinazolines with bulky dibenz[b,f]azepine and dibenzo[a,d]‐cycloheptene substituents at the 6‐position as inhibitors of dihydrofolate reductases from pneumocystis carinii,toxoplasma gondii,and mycobacterium avium

The synthesis of four previously undescribed 2,4‐diaminopyrido[2,3‐d]pyrimidines ( 3,4 ) and 2,4‐diaminoquinazolines ( 5,6 ) with a bulky tricyclic aromatic group at the 6‐position is described. Condensation of dibenz[b,f]azepine with 2,4‐diamino‐6‐bromomethylpyrido[2,3‐d]pyrimidine ( 8 ) and 2,4‐diamino‐6‐bromomethylquinazoline ( 17 ) in the presence of sodium hydride afforded N‐[(2,4‐diaminopyrido[2,3‐d]‐pyrimidin‐6‐yl)methyl]dibenz[b,f]azepine ( 3 ) and N‐[(2,4‐diaminoquinazolin‐6‐yl)methyl]dibenz[b,f]‐azepine ( 4 ), respectively. Condensation of 5‐chlorodibenzo[a,d]cycloheptene ( 19 ) and 5‐chloro‐10,11‐dihydrodibenzo[a,d]cycloheptene ( 20 ) with 2,4,6‐triaminoquinazoline ( 13 ) afforded 5‐[(2,4‐diamino‐quinazolin‐6‐yl)amino]‐5H‐dibenzo[a,d]cycloheptene ( 5 ) and the corresponding 10,11‐dihydro derivative ( 6 ), respectively. The bromides 8 and 17 , as hydrobromic acid salts, were obtained from the corresponding nitriles according to a standard three‐step sequence consisting of treatment with Raney nickel in formic acid followed by reduction with sodium borohydride and bromination with dry hydrogen bromide in glacial acetic acid. Compounds 3–6 were evaluated in vitro for the ability to inhibit dihydrofolate reductase from Pneumocystis carinii, Toxoplasma gondii, Mycobacterium avium, and rat liver. Compounds 3 and 4 were potent inhibitors of all four enzymes, with IC₅₀ values in the 0.03–0.1 μM range, whereas 5 was less potent. However the selectivity of all four compounds for the parasite enzymes relative to the rat enzyme was<10‐fold, whereas the recently reported lead compound in this series, N‐[(2,4‐diaminopteridin‐6‐yl)methyl]dibenz[b,f]azepine ( 1 ) has > 100‐fold selectivity for the T. gondii and M. avium enzyme and 21‐fold selectivity for the P carinii enzyme.     

Synthesis and antifolate activity of new pyrrolo[2,3‐d]pyrimidine and thieno[2,3‐d]pyrimidine inhibitors of dihydrofolate reductase

Three previously undescribed dihydrofolate reductase (DHFR) inhibitors, N^α‐[4‐[N‐[(2,4‐diaminopyrrolo[2,3‐d]pyrimidin‐5‐yl)methyl]amino]benzoyl]‐N^δ‐hemiphthaloyl‐L‐ornithine (7) , N^α‐ [4‐ [N‐[(2,4‐diaminothieno[2,3‐d]pyrimidin‐5‐yl)methyl]amino]benzoyl]‐ N^δ‐hemiphthaloyl‐L‐ornithine (8) , and N‐[4‐[N‐[(2,4‐diaminothieno[2,3‐d]pyrimidin‐5‐yl)methyl]amino]benzoyl]‐L‐glutamic acid (12) , were synthesized and their antifolate activity was assessed. The ability of 7 and 8 to bind to DHFR and inhibit the growth of CCRF‐CEM human lymphoblastic leukemia cells in culture were dramatically reduced in comparison with the corresponding pteridine analogue, N^α‐(4‐amino‐4‐deoxypteroyl)‐N^δ‐hemiphmaloyl‐L‐ornithine ( 1 , PT523). In a similar manner, the antifolate activity of 12 was markedly reduced in comparison with that of the corresponding glutamate analogue, aminopterin ( 5 , AMT). In contrast, 7, 8 , and 12 all displayed excellent affinity for the reduced folate carrier (RFC) of CCRF‐CEM cells as measured by a standard competitive influx assay. Lack of a consistent correlation between the results of the growth inhibition assays and those of the DHFR and RFC binding assays results suggest that additional factors also play a role in the antifolate activity of these compounds.     

Synthesis of New Furo[2,3‐d]pyrimidines and Pyrimido[4′,5′:4,5]furo[2,3‐d]pyrimidines

Sodium salt of 4‐hydroxy‐6‐methyl‐2‐phenylpyrimidine‐5‐carbonitrile ( 3 ) was subjected to alkylation with different a‐halo compounds, where the corresponding O‐alkylated products 4_a‐g were obtained. Ring closure of the O‐alkylated product 4_a‐c performed using sodium ethoxide in refluxing ethanol afforded furo[2,3‐d]pyrimidines 5_a‐c The latter compounds on reaction with a variety of reagents gave other new furopyrimidines as well as a number of furodipyrimidines.     

Furo[2,3‐d]pyrimidines and Oxazolo[5,4‐d]pyrimidines as Inhibitors of Receptor Tyrosine Kinases (RTK)

Receptor tyrosine kinases such as VEGFR2 (vascular endothelial growth factor receptor 2, KDR) or EGFR (epidermal growth factor receptor) play crucial roles in a variety of diseases, such as cancer. Recently, some pyrrolopyrimidines were shown to be potent EGFR inhibitors. Therefore, new types of oxazolo[5,4‐d]pyrimidines and furo[2,3‐d]pyrimidines were synthesized (Schemes 1 and 2). Appropriately substituted derivatives of these classes of compounds inhibited VEGFR2 and EGFR with IC₅₀ values in the low nanomolar range (see Table). Generally, the furopyrimidines were somewhat more active than the oxazolopyrimidines. The best inhibitors, 20m, 20p , and 20r , had an IC₅₀ of 3 nM towards EGFR and showed a good selectivity, being distinctly less active towards VEGFR2.     

Synthesis of new thieno[2,3‐d]pyrimidines,thieno[3,2‐e]pyridines,and thieno[2,3‐d][1,3]oxazines

o‐Aminothiophene dicarbonitrile 1 on neat reaction with cyclic ketones in anhydrous ZnCl₂ yielded mixture of fused aminopyridine 3 and iminospirooxazine 4 derivatives. Similarly, pyrimidine derivatives 5 and 8 were obtained by the reaction of this intermediate 1 with formic acid and DMF‐DMA followed by hydrazine hydrate, respectively. The reaction of o‐amino‐thiophene dicarboxamide 2 at ambient temperature with cyclic ketones yielded spiropyrimidine 10 as a sole product in quantitative yield. The regioselective anellated pyrimidine 9 , 11 , and dihydropyrimidine 12 derivatives were also obtained by the reaction with aromatic aldehydes in presence of piperidine and iodine respectively. J. Heterocyclic Chem., (2012).     

Ring closure reactions of pyrido[2,3‐d]pyrimidines to pyrano[2′,3′:4,5]‐ and oxazolo[5′,4′:4,5]pyrido[2,3‐d]pyrimidines

The cyclocondensation of 5‐hydroxy‐pyrido[2,3‐d]pyrimidines 1 with malonates gives pyrano[2′,3′:4,5]‐pyrido[2,3‐d]pyrimidines 2 . Nitration of 1 and reduction with zinc in the presence of carboxylic acids/anhydrides gave 2‐alkyloxazolo[5′,4′:4,5]pyrido[2,3‐d]pyrimidines 4 , which were ring‐opened to 6‐aminopyrido[2,3‐d]pyrimidines 5, 6 and 7 . Cyclization of 6‐aminopyrido[2,3‐d]pyrimidines 6 with benzoylchlorides 8 gave 2‐aryloxazolo[5′,4′:4,5]pyrido[2,3‐d]pyrimidines 9 . Reaction conditions for the cyclization have been studied by differential scanning calorimetry (DSC).     

Synthesis of 5‐mono‐ and 5,7‐diamino‐pyrido[2,3‐d]‐pyrimidinediones with potential biological activity by regioselective amination

5‐Alkyl‐/arylamino‐ and 5,7‐dialkyl/arylamino‐pyrido[2,3‐d]pyrimidine‐2,4‐diones ( 4,5, 7‐9 ) were prepared from the corresponding 5,7‐dichloro‐pyrido[2,3‐d]pyrimidine‐2,4‐diones 2 with aliphatic and aromatic amines 3 and 6 in a regioselective reaction. The 7‐monoazides 10 , obtained by azidation of 5‐amino‐7‐chloro derivatives 4 , were converted to iminophosphoranes by reaction with triphenyl‐phosphane via Staudinger reaction. Hydrolysis with aqueous acetic acid produced in one step 7‐unsubstituted‐amino‐pyrido[2,3‐d]pyrimidine‐2,4‐diones 12 . In a similar amination reaction, 5‐chloropyrido[2,3‐d]pyrimidine‐2,4,7‐triones 13 were aminated and formylated to 5‐alkyl/arylamino‐6‐formyl derivatives 14 ‐ 16 in a combined one‐step‐reaction with bulky arylamines or alkylamines in the presence of dimethylformamide.     

Facile Methods for the Synthesis of 5‐Aryl and 5‐Iodo Pyrrolo[2,3‐d]pyrimidines

An efficient and environmentally benign one‐pot method has been developed for the synthesis of 4‐amino‐5‐arylpyrrolo[2,3‐d]pyrimidines. Phthalimido acetophenones were reacted with cyanoacetamide to give 2‐amino‐4‐phenyl‐1H‐pyrrole‐3‐carboxamides, which were further converted to 5‐aryl‐3H‐pyrrolo[2,3‐d]pyrimidin‐4‐ones. A novel method is also developed for the synthesis of 4‐amino‐5‐iodopyrrolo[2,3‐d]pyrimidines.     

Synthesis of 2‐amino‐4‐oxo‐5‐substitutedbenzylthiopyrrolo[2,3‐d]‐pyrimidines as potential inhibitors of thymidylate synthase

A series of ten novel 2‐amino‐4‐oxo‐5‐[(substitutedbenzyl)thio]pyrrolo[2,3‐d]pyrimidines 2‐11 were synthesized as potential inhibitors of thymidylate synthase and as antitumor agents. The analogues contain various electron withdrawing and electron donating substituents on the benzylsulfanyl ring of the side chains and were synthesized from the key intermediate 2‐amino‐4‐oxo‐6‐methylpyrrolo[2,3‐d]pyrimidine, 14 . Appropriately substituted benzyl mercaptans were appended to the 5‐position of 14 via an oxidative addition reaction using iodine, ethanol and water. The compounds were evaluated against human, Escherichia coli and Toxoplasma gondii thymidylate synthase and against human, Escherichia coli and Toxoplasma gondii dihydrofolate reductase. The most potent inhibitor, ( 6 ) which has a 4′‐methoxy substituent on the side chain, has an IC₅₀=25 μM against human thymidylate synthase. Contrary to analogues of general structure 1 , electron donating or electron withdrawing substituents on the side chain of 2‐11 had little or no influence on the human thymidylate synthase inhibitory activity.     

An Efficient Synthesis of Tetracyclic Pyrano[2,3‐d]pyrimidines

A series of pyrano[2,3‐d ]pyrimidine derivatives have been synthesized by the reaction of 2‐amino‐3‐cyano‐4H‐pyrans and acetic anhydride with acid catalyst . This method is very efficient because of short reaction times and easy work‐up, and it provides an efficient and promising synthetic strategy for the construction of the tetracyclic pyrano[2,3‐d ]pyrimidine skeleton. The X‐ray crystal structures of products are confirmed, and the possible mechanism is provided in this paper.     

Synthesis of New Imino Containing Tetrahydrochromeno[2,3‐d]pyrimidines

Some new derivatives of 3,5‐diaryl‐4‐imino‐5,7,8,9‐tetrahydro‐3H‐chromeno[2,3‐d ]pyrimidine have been prepared through a condensation reaction of 2‐amino‐4‐aryl‐3‐cyano‐5,6,7,8‐tetrahydrobenzo[b ]pyrans with triethyl orthoformate in boiling acetic anhydride followed by cyclization with primary aryl amines in the presence of a few drops triethylamine as catalyst in refluxing ethanol. The products were characterized on the basis of IR, ¹H‐NMR, and ¹³C‐NMR spectral and microanalytical data.     

One‐pot synthesis of novel substituted pyrrolo[2,3‐d]pyrimidines using dry media

A convenient solvent‐free one‐pot synthesis of 1,3,5,7‐tetraaryl‐1,3,4,7‐tetrahydro‐2‐thio‐xopyrrolo[2,3‐d]pyrimidin‐4‐one derivatives using supported reagents under microwave irradiation is described. © 2007 Wiley Periodicals, Inc. Heteroatom Chem 18:617–621, 2007; Published online in Wiley InterScience ( www.interscience.wiley.com ). DOI 10.1002/hc.20355     

Paal knorr reaction for novel pyrrolo[2,3‐d]pyrimidines

An expeditious and convenient solid supported synthesis of 1,3,7‐triaryl‐6‐phenyl‐2‐thioxo‐1,2,3,7‐tetrahydropyrrolo [2,3‐d]pyrimidin‐4‐one derivatives from readily accessible N,N‐disubstituted thiobarbituric acids under microwaves utilising Paal Knorr reaction is described.     

Design,synthesis, and antimicrobial activity of some new pyrazolo[3,4‐d]pyrimidines

2‐Benzyl‐ and 2‐aryloxymethyl‐3‐amino‐1‐phenyl‐pyrazolo[3,4‐d]pyrimidine‐4‐ones 5a–f have been synthesized by reacting the corresponding arylacetylamino derivatives 3a–f with hydrazine hydrate. Thionation of compounds 5d–f by action of P₂S₅ in pyridine yielded 2‐aryloxy‐methyl‐3‐amino‐1‐pheny‐lpyrazolo[3,4‐d]pyrimidin‐4‐thions 6a–c . 2,5‐Diphenyl‐2,3‐dihydro‐1H‐pyrazolo[5′,1′:4:5]pyrazolo[3,4‐d]pyrimidine‐8‐one ( 8 ) was also obtained via reaction of ethyl‐2‐cinnamoylamino‐1‐phenyl‐pyrazole‐4‐car‐boxylate ( 7 ) with hydrazine hydrate. The prepared compounds were screened in vitro for their antimicrobial activity. Some of the tested compounds were found to be active at 100 μg/ml compared with reference compounds (Ampicillin and Trivid) as antibacterial agents and claforan as antifungal agent. © 2003 Wiley Periodicals, Inc. Heteroatom Chem 14:530–534, 2003; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/hc.10187     

Synthesis of novel,nonclassical 2‐amino‐4‐oxo‐6‐(arylthio)ethylpyrrolo[2,3‐d] pyrimidines as potential inhibitors of thymidylate synthase

A novel series of 14 nonclassical 6‐substituted pyrrolo[2,3‐d]pyrimidines 2a ‐ 2n were designed as potential inhibitors of thymidylate synthase, based on previously reported 2‐amino‐4‐oxopyrrolo[2,3‐d]‐pyrimidines 1a and 1b . The synthesis of the target compounds 2a‐2n was accomplished by nucleophilic displacement of the mesylate 11 with appropriately substituted aromatic thiols. Most of the target compounds did not show inhibition of either Escherichia coli thymidylate synthase or recombinant human thymidylate synthase at the concentrations tested. However, compounds 2h (2,4‐dichloro), 2j (3,4‐dichloro) and 2m (4‐nitro) did show 25%, 40% and 35% inhibition of human thymidylate synthase at 23 μM, 23 μM and 24 μM, respectively. These observations are in accordance with previous reports, which suggest that strong electron withdrawing substituents on the side chain aromatic ring are conducive to inhibition of thymidylate synthase.